Lilly’s Zyprexa Pact With Health Providers Wins Approval
This article is for subscribers only.
Eli Lilly & Co. won approval of a $4.5 million settlement with five union health funds and an insurer that alleged improper marketing of its best-selling medication Zyprexa raised their costs.
U.S. District Judge Jack Weinstein in Brooklyn, New York, approved the settlement at a hearing today. The so-called third-party payors claimed Indianapolis-based Eli Lilly’s marketing of Zyprexa, a schizophrenia treatment, caused them to pay more for the drug than what it was worth. A plaintiffs’ expert had estimated damages in the case as high as $7.7 billion, according to a 2010 appeals-court decision.